- |||||||||| memantine / Generic mfg., rivastigmine / Generic mfg.
Comparative efficacy of pharmacological cognitive treatments in Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1514;
Rivastigmine is likely to offer the highest clinical, cognitive, and neuropsychiatric benefits in PDD and DLB patients compared to the other cognitive treatments. More large head-to-head randomized controlled trials are needed for better evaluation and enhancement of our current treatment protocols.
- |||||||||| donepezil / Generic mfg., rivastigmine / Generic mfg.
Compliance with national and international guidelines in the treatment of non-motor symptoms in late stage Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_577;
The results confirm that NMS are common and pronounced in late stage PD and the present analyses strongly suggest a clear need for clinicians to further screen for and treat NMS also in this group. Optimizing treatment of NMS according to the national and international treatment guidelines may improve symptomatology and enhance quality of life in late stage PD.
- |||||||||| RGFP966 / BioMarin, tasquinimod (ABR-215050) / Active Biotech, Ipsen, Cognex (tacrine) / Shionogi
Review, Journal: Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease (Review). (Pubmed Central) - Aug 24, 2023
However, further evaluations need to be performed to determine the optimal treatment. The present study reviews recent interventions for enhancing adult neurogenesis and attempts to elucidate their mechanisms of action, which may provide a theoretical basis for inducing nerve regeneration to fight against AD.
- |||||||||| clonazepam / Generic mfg., rivastigmine / Generic mfg.
Journal: REM Sleep Behavior Disorder and Other REM Parasomnias. (Pubmed Central) - Aug 21, 2023
Individuals who wish to know about the associated risk should be counseled accordingly to allow planning and involvement in research if they choose. Exercise may have some neuroprotective effects, although no treatment has been shown to modify the neurodegenerative risk.
- |||||||||| rivastigmine / Generic mfg.
Journal: Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias. (Pubmed Central) - Aug 7, 2023
Cumulatively, these data support that the conclusion that cholinesterase inhibition has relatively specific and circumscribed-rather than global-effects on attention that may also affect performance on simple short-term memory tasks, but not when cognitive control over working memory is required. The results also indicate that the withdrawal of a single dose of rivastigmine is sufficient to reveal these impairments, demonstrating that cholinergic withdrawal can be an informative clinical as well as an investigative tool.
- |||||||||| Nuplazid (pimavanserin) / Acadia Pharma
Journal: Cholinesterase Inhibitors for Delusions and Hallucinations in Alzheimer Disease and Parkinson Disease: Questionably Significant Benefits. (Pubmed Central) - Aug 2, 2023
Whereas the signal identified in this meta-analysis merits examination in appropriately designed RCTs, the findings of the meta-analysis may not much change current treatment strategies because patients with dementia would probably anyway receive a ChEI. Therefore, if psychotic symptoms persist for 24 weeks despite optimally dosed ChEI treatment, and if behavioral and psychosocial interventions do not help, clinicians may need to consider the potential benefits vs risks of other drugs, such as atypical antipsychotics and pimavanserin, in a shared decision-making process.
- |||||||||| rivastigmine / Generic mfg.
Clinical, Journal: The impact of rivastigmine on post-surgical delirium and cognitive impairment; a randomized clinical trial. (Pubmed Central) - Jul 28, 2023
The continuation of systematic research efforts and the provision of individualized treatment for patients suffering from these disorders is vital. The significant result of our randomized clinical trial is that pre-op Rivastigmine treatment may be associated with a substantial drop in patients experiencing post-op delirium and post-op cognitive impairment.
- |||||||||| memantine / Generic mfg., LMTX (hydromethylthionine) / TauRx, rivastigmine / Generic mfg.
Preclinical, Journal: Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice. (Pubmed Central) - Jul 18, 2023
In summary, traditional anti-dementia drugs impair mitochondrial function while HMT has no adverse effects on mitochondrial respiration in tau-transgenic mice. These results support the further development of HMT as an anti-dementia drug.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Continuation rates of newly prescribed donepezil among patients with Alzheimer () - Jul 6, 2023 - Abstract #AAIC2023AAIC_9219;
Conclusion The AD patients showed a rapid discontinuation of donepezil and subsequent AD treatments by 90 days, and approximately 40% had ceased this therapy after 1.5 years. In view of the limited pharmaceutical options available for AD in Japan, this finding emphasizes the need for AD preventive measures in the pre-clinical stage.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
The Availability and Use of Anti-Dementia Drugs: An International Survey (Hall 5) - Jul 6, 2023 - Abstract #AAIC2023AAIC_9034;
There are concerns that without access to commonly prescribed anti-dementia drugs, this may introduce harms to people with dementia as they could be prescribed antipsychotics instead. Emphasis should be given to find ways for all people living with dementia, regardless of geographic or socioeconomic status, to access effective and safe anti-dementia drugs such as donepezil.
- |||||||||| donepezil / Generic mfg.
Investigating the role of Donepezil in promoting Oligodendrocyte precursor cell (OPC) differentiation and Therapeutic Potential in Alzheimer's Disease (AD). (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_8053;
Data suggest not only a reduced cognitive efficacy of HMT in subjects pre-exposed to the choline esterase inhibitor rivastigmine, but also offer mechanistic explanations for potential interactions at presynaptic function and for transmitter release. Background: Statistical analysis of myelin basic protein (MBP) cells generated from Neural progenitor cell (NPC)-derived Oligodendrocyte precursor cells (OPCs) treated with various AChEIs, including donepezil, huperzine A, rivastigmine and tacrine, revealed that only donepezil is capable of facilitating OPC-to-OL formation, indicating that donepezil
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7737;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7528;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Symptomatic Alzheimer's Disease Therapy Utilization in 3 National Cohorts (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6792;
Time on first therapy was relatively short (<1 year) and the majority of patients did not utilize a second therapy. These results underscore the unmet need for additional therapies to alleviate the significant burden of AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Drug utilization among patients with mild cognitive impairment and Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6679;
The proportion of MCI and/or AD cases with prescriptions were similar across genders. The proportion with prescriptions was generally lowest among African Americans.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5671;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5462;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Cholinesterase inhibitors, cognitive decline, major cardiovascular events, and mortality in dementia with Lewy bodies (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_4533;
This may be explained by its modulatory effect on nicotinic receptors as well as its inhibitory effect on acetylcholinesterase. Interestingly, in contrast to our previous findings in AD, ChEI-treatment in DLB was not associated with reduced MACE or mortality risk, which might be related with the more prominent autonomic dysfunction in DLB than in AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3425;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3216;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1205;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_996;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| risperidone / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Retrospective data, Journal: Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis. (Pubmed Central) - Jul 3, 2023
MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available. Despite the scarcity of high-quality evidence, risperidone is probably the best pharmacological option to consider for alleviating NPS in people with dementia in short-term treatment when considering the risk-benefit profile of drugs.
- |||||||||| galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Journal: A Novel Formulation: Donepezil Patch. (Pubmed Central) - Jul 3, 2023
In 2022, the US Food and Drug Administration approved a novel patch formulation for donepezil that could be beneficial for patients with dysphagia as well as potentially decreasing the side effect burden. The purpose of this analysis is to review the efficacy, safety, tolerability, and clinical considerations related to this novel formulation.
|
